欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号IS/H/0535/001
药品名称Eribulin Advanz Pharma
活性成分
    • Eribulin mesilate 0.44 mg/ml
剂型Solution for injection
上市许可持有人ADVANZ PHARMA Limited Suite 17, Northwood House Northwood Avenue, Santry Dublin 9 Ireland
参考成员国 - 产品名称Iceland (IS)
Eribulin Advanz Pharma 0,44 mg/ml Stungulyf, lausn
互认成员国 - 产品名称
    • Ireland (IE)
    • Austria (AT)
    • France (FR)
    • Spain (ES)
    • Portugal (PT)
    • Italy (IT)
    • Sweden (SE)
    • Norway (NO)
    • Finland (FI)
    • Belgium (BE)
许可日期2023/06/06
最近更新日期2025/01/03
药物ATC编码
    • L01XX41 eribulin
申请类型
  • TypeLevel1:Abridged
  • TypeLevel2:Initial Application
  • TypeLevel3:Generic Art 10.1 and 10.2 Dir 2001/83/EC
  • TypeLevel4:Chemical Substance
  • TypeLevel5:Prescription Only
附件文件下载
市场状态Positive
©2006-2025 Drugfuture->European Union HMA Authorisation of Medicines DataBase